Cellbion셀비온
308430 · KOSDAQ · ₩308430 · 셀비온
- Market cap
- ₩154B
- Enterprise value
- ₩93B
- P/E
- 17.7×
- P/B
- 4.3×
- Dividend yield
- 0.0%
- ROE
- 24.1%
- Net margin
- 406.5%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−71.7% from the high
₩9,930Today: ₩11,330 – ₩12,460₩42,200
Returns
- 1W−6.8%
- 1M−19.3%
- 3M+12.4%
- 6M−68.0%
- YTD−49.4%
- 1Y−27.2%
- Volume today
- 23,809
- 0.7× the 20-day average
- Traded today
- ₩281M
- Listed shares
- 12,905,251
- EPS (12 months)
- ₩676
- Earnings yield 5.7%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Why is it moving?
+5.5% on Oct 28, 2026.
We found no news, filing or broker report explaining it yet. Moves without news happen; it may come later.
Possible reasons, not certainties. Not financial advice.
Signals
Quiet- BuzzQuietBuzz 39 of 100 (50 is a normal day for this stock).
- MomentumWeak-18.8% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Cellbion stock overview
Cellbion (셀비온, KRX: 308430) is listed on KOSDAQ, in the Biotech & Pharma sector. Cellbion is a South Korean company focused on precision medicine through theranostics, developing radiopharmaceutical drugs mainly for cancer treatment and diagnosis. Its shares closed at ₩11,940 on Oct 28, 2026, up 5.48% on the day, giving it a market value of ₩154B.
Key facts
- Market cap
- ₩154B
- Sector
- Biotech & Pharma
- Latest price change
- +5.48%
- As of
- Oct 28, 2026
- Main business
- Cellbion is a South Korean company focused on precision medicine through theranostics, developing radiopharmaceutical drugs mainly for cancer treatment and diagnosis.
Quick answers about Cellbion
- What does Cellbion do?
- Cellbion is a South Korean company focused on precision medicine through theranostics, developing radiopharmaceutical drugs mainly for cancer treatment and diagnosis. Its lead candidate, Lu-177-Pocuvotide, targets the PSMA protein for prostate cancer and is paired with a companion diagnostic, Ga-68-NGUL. The company also has a pipeline of targeted cancer therapies and imaging agents, and is pursuing open innovation partnerships with domestic and foreign drug developers.
- What is the market cap of Cellbion?
- The market capitalisation of Cellbion was ₩154B at the close on Oct 28, 2026.
- Who are the largest shareholders of Cellbion?
- According to the latest official filings, the largest reported holders are Kim Kwon (36.99%, as of Oct 22, 2024); Samho Green Investment (3.56%, as of Oct 23, 2024); Park Jae-min (0.59%, as of May 15, 2026).
- When is the next earnings report from Cellbion?
- Korean companies rarely announce results dates in advance. Based on when Cellbion filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
Company profile
Cellbion is a South Korean company focused on precision medicine through theranostics, developing radiopharmaceutical drugs mainly for cancer treatment and diagnosis. Its lead candidate, Lu-177-Pocuvotide, targets the PSMA protein for prostate cancer and is paired with a companion diagnostic, Ga-68-NGUL. The company also has a pipeline of targeted cancer therapies and imaging agents, and is pursuing open innovation partnerships with domestic and foreign drug developers.
Written by AI from the company's latest annual report.
- Korean name
- 셀비온
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 김권
- Founded
- Jul 2010
- Listed
- Oct 2024
- Listed shares
- 12,905,251
- Fiscal year ends
- Month 12
- Website
- cellbion.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent filings
See all- Major management matter relevant to investorsSep 29, 2026
- Half-year report (Jun 2026)Aug 13, 2026
- Major management matter relevant to investorsJun 30, 2026
- Insider shareholding reportMay 15, 2026
- Quarterly report (Mar 2026)May 14, 2026
Titles in Korean until English translations are added.
Also known as: Cellbion / 셀비온 / 308430 / KRX:308430
Source: KRX statistical information